Diagnostics in a Post PAMA Marketplace


Biotechnology Industry Organization

1201 Maryland Avenue Southwest
9th Floor
Washington, DC 20024

Directions »


May 14, 2014 12:00PM–3:00PM

On April 1, the Protecting Access to Medicare Act of 2014 (PAMA) was enacted into law.  Section 216, entitled Improving Medicare Policies for Clinical Diagnostic Laboratory Tests, modernizes the Medicare payment system for clinical laboratory tests with the establishment of a market-based payment system. This is the most significant modernization of the Clinical Laboratory Fee Schedule (CLFS) since the introduction of the CLFS in 1984.  

Please click here for a summary of the CLFS Reform Provisions.

A Panel Discussion With

Dan Todd, Health Policy Advisor, Senate Finance Committee - PAMA Overview / CLFS Reform to Market Based Pricing

Elaine Jeter, M.D., Medical Director, Palmetto GBA - What to Expect from Private Payers and the Role of MolDx

Louis Jacques, M.D., ADVI (former Director, Coverage & Analysis Group, CMS) - The role of CMS and FDA in Clinical Utility 

Brian Carey, Foley Hoag, LLP - Issues to Watch for Implementation

Marc Samuels, ADVI
Bruce Quinn, M.D., Ph.D., Foley Hoag LLP

Sponsored by: